KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Operating Margin (2016 - 2025)

Historic Operating Margin for Sarepta Therapeutics (SRPT) over the last 12 years, with Q2 2025 value amounting to 18.91%.

  • Sarepta Therapeutics' Operating Margin rose 191100.0% to 18.91% in Q2 2025 from the same period last year, while for Jun 2025 it was 16.16%, marking a year-over-year increase of 136400.0%. This contributed to the annual value of 11.47% for FY2024, which is 330100.0% up from last year.
  • According to the latest figures from Q2 2025, Sarepta Therapeutics' Operating Margin is 18.91%, which was up 191100.0% from 24.56% recorded in Q4 2024.
  • Sarepta Therapeutics' Operating Margin's 5-year high stood at 24.56% during Q4 2024, with a 5-year trough of 103.36% in Q1 2021.
  • Moreover, its 5-year median value for Operating Margin was 41.21% (2022), whereas its average is 32.67%.
  • As far as peak fluctuations go, Sarepta Therapeutics' Operating Margin skyrocketed by 770400bps in 2021, and later plummeted by -388500bps in 2022.
  • Over the past 5 years, Sarepta Therapeutics' Operating Margin (Quarter) stood at 52.52% in 2021, then increased by 21bps to 41.34% in 2022, then surged by 115bps to 6.21% in 2023, then surged by 296bps to 24.56% in 2024, then fell by -23bps to 18.91% in 2025.
  • Its Operating Margin was 18.91% in Q2 2025, compared to 24.56% in Q4 2024 and 4.75% in Q3 2024.